- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Emerald Health Shares Data of Patented Cannabinoid Against Parkinson’s Disease
A division of Emerald Health Therapeutics announced key members of its scientific team found the potential for EHP-102 to treat Parkinson’s disease.
Emerald Health Pharmaceuticals, a division of Emerald Health Therapeutics (TSXV:EMH), announced key members of its scientific team found the potential for EHP-102, a patented aminoquinone derivative of the non-psychoactive phytocannabinoid, to treat Parkinson’s disease.
As quoted in the press release:
This research was done in collaboration with Professor Javier Fernandez-Ruiz (University Complutense of Madrid, Spain).
These results were published in the Journal of Neuroinflammation in a scientific paper entitled, “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor.” Co-authors of this paper included Eduardo Muñoz, MD, PhD, EHP’s Chief Scientific Officer and Mari-Luz Bellido, PhD, EHP’s Vice President of European Operations.
Researchers evaluated the anti-inflammatory and neuroprotective properties of EHP-102 in two animal models of Parkinson’s disease, as well as in vitro cellular models. Findings showed that EHP-102 is neuroprotective against inflammation-driven neuronal damage in these models. EHP-102 is a peroxisome proliferator-activated receptor-γ (PPARγ) modulator acting on both the canonical and alternative binding sites. These data demonstrate that EHP-102 could potentially be used as a neuroprotective agent in Parkinson’s disease due to its multi-target properties specific to the disease.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.